Gelonghui, January 30丨Eddy Pharmaceutical (688488.SH) announced its 2023 annual results forecast. According to preliminary estimates by the finance department, the company's annual revenue for 2023 is expected to be about 416.585 million yuan, an increase of about 172.3612 million yuan compared with the previous year, an increase of about 70.58%. Among them, revenue from innovative anti-HIV drugs is expected to be 73.5788 million yuan, an increase of 119.67% year on year. Revenue from crude human protein products is estimated to be 262.20.29 million yuan, an increase of 82.82% year on year;
The net profit attributable to the owner of the parent company is expected to be about -63.0 million yuan to -90 million yuan in 2023. Compared with the previous year, the loss will be reduced by about 61.2027 million yuan to 34.2027 million yuan, and the loss margin will decrease by about 49.28% to 27.54% year on year;
It is estimated that in 2023, net profit attributable to owners of the parent company will be about -77.00 million yuan to -10,400.00 million yuan. Compared with the previous year, the loss will be reduced by about 76.389 million yuan to 49.389 million yuan, and the loss margin will decrease by about 49.80% to 32.20% year on year.